Dr. Goy on Immunotherapy in Mantle Cell Lymphoma

Andre Goy, MD
Published: Tuesday, Sep 04, 2018



Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).

Lenalidomide (Revlimid) and rituximab (Rituxan; R2) plus ibrutinib (Imbruvica) is a combination approach of immunotherapy and targeted therapy, explains Goy. At John Theurer Cancer Center, 71% of heavily pretreated patients with MCL experienced a complete response with the regimen. Additionally, a published study showed high response rates in patients with poor genetic risk factors.

Traditionally, when physicians think about immunotherapy, they think about chimeric antigen receptor T cells, says Goy. However, a lot remains unknown about the use of checkpoint inhibitors in MCL. Activity outside of primary mediastinal lymphoma and Hodgkin lymphoma has been relatively disappointing, explains Goy. However, there is a lot of potential with anti–CD47 antibodies that may enable physicians to give patients a biological induction, and subsequently consider immunotherapy in high-risk patients.
SELECTED
LANGUAGE


Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the potential of immunotherapy in patients with mantle cell lymphoma (MCL).

Lenalidomide (Revlimid) and rituximab (Rituxan; R2) plus ibrutinib (Imbruvica) is a combination approach of immunotherapy and targeted therapy, explains Goy. At John Theurer Cancer Center, 71% of heavily pretreated patients with MCL experienced a complete response with the regimen. Additionally, a published study showed high response rates in patients with poor genetic risk factors.

Traditionally, when physicians think about immunotherapy, they think about chimeric antigen receptor T cells, says Goy. However, a lot remains unknown about the use of checkpoint inhibitors in MCL. Activity outside of primary mediastinal lymphoma and Hodgkin lymphoma has been relatively disappointing, explains Goy. However, there is a lot of potential with anti–CD47 antibodies that may enable physicians to give patients a biological induction, and subsequently consider immunotherapy in high-risk patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x